“We observed …that patients treated with hydroxychloroquine had a 30% lower in-hospital mortality rate compared to those not receiving this treatment. Our data were subjected to extremely rigorous statistical analysis, taking into account all the variables and possible confounding factors that could come into play. The drug efficacy was evaluated in various subgroups of patients. The positive results of hydroxychloroquine treatment remained unchanged, especially in those patients showing a more evident inflammatory state at the moment of admission to hospital.”
Published in European Journal of Internal Medicine.
3,451 patients in 33 hospitals.
https://scitechdaily.com/risk-of-death-is-30-lower-for-covid-19-patients-treated-with-hydroxychloroquine/amp/?__twitter_impression=true
#medicine #healthcare #coranavirus #covid19data #sarscov2 #covid
Like this:
Like Loading...
About budbromley
Bud is a retired life sciences executive. Bud's entrepreneurial leadership exceeded three decades. He was the senior business development, marketing and sales executive at four public corporations, each company a supplier of analytical and life sciences instrumentation, software, consumables and service. Prior to those positions, his 19 year career in Hewlett-Packard Company's Analytical Products Group included worldwide sales and marketing responsibility for Bioscience Products, Global Accounts and the International Olympic Committee, as well as international management assignments based in Japan and Latin America. Bud has visited and worked in more than 65 countries and lived and worked in 3 countries.
budbromley 